Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Syfovre
Pharma
Apellis reports 4% sales drop for eye disease med Syfovre
In a preliminary report of 2025 results, Apellis said that sales of its GA drug Syfovre came in at $587 million for the year, a 4% decline from 2024.
Kevin Dunleavy
Jan 12, 2026 1:06pm
With sales turnaround, Astellas projects big growth for Izervay
Jul 10, 2025 4:30pm
Apellis' Syfovre faces tough road ahead in GA market: analyst
May 14, 2025 11:10am
Apellis, AstraZeneca break down their #FierceMadness success
Apr 15, 2025 1:25pm
Apellis expects sales of Syfovre to decline in Q1
Feb 28, 2025 3:05pm
Astellas' Izervay wins key FDA label update after prior rejection
Feb 13, 2025 12:00pm
